precision medicine

Research in Review

08/22/2016

JCP Editors

Inhibition of oncogenic protein BMI1 may offer a therapeutic benefit for certain patients with lung cancer, according to the results of an analysis published in Science Translational Medicine. In a prior study,...

...

08/22/2016

Journal of Clinical Pathways

Quiz

Friday Morning Quiz ‚Äì Week of August 15-21

08/18/2016

JCP Editors

A recent study of non-small cell lung cancer found that those with epidermal growth factor receptor (EGFR)-positive disease were at an increased likelihood of developing leptomeningeal metastases (LM), but that...

A...

08/18/2016

Journal of Clinical Pathways

Research in Review

ESR1 Mutations May Affect Treatment for Metastatic Breast Cancer

08/16/2016

JCP Editors

Estrogen receptor α (ESR1) mutations are highly prevalent in women receiving aromatase inhibitors for metastatic breast cancer (MBC), according to a secondary analysis from a clinical trial. ESR1 mutations found in...

...

08/16/2016

Journal of Clinical Pathways

Research in Review

Treatment Combination Improves NSCLC Survival and Response

08/12/2016

JCP Editors

East Asian patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and epidermal growth factor receptor mutations may benefit from treatment with pemetrexed plus gefitinib, results from a phase II...

East...

08/12/2016

Journal of Clinical Pathways

Research in Review

Equivalent Outcomes With Two NSCLC Treatment Options

08/04/2016

JCP Editors

Erlotinib may be an effective therapeutic option for patients with pretreated advanced non-small cell lung cancer (NSCLC) and no known molecular alterations, according to a study published in the journal Lung...

...

08/04/2016

Journal of Clinical Pathways

Research in Review

Radiotherapy Use and Effectiveness in Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma

08/02/2016

JCP Editors

A study of adjuvant chemoradiotherapy (CRT) and boost doses of postoperative radiotherapy (B-PORT) in oropharyngeal squamous cell carcinoma (OSCC) has found that outcomes depend on a number of pathologic and...

...

08/02/2016

Journal of Clinical Pathways

Research in Review

Protein Predicts Prognosis in Gastric Cancer

08/02/2016

JCP Editors

The protein calpain-9 may be an independent factor for poor prognosis that, when combined with TNM stage, may provide a better predictive model for outcomes in patients with gastric cancer, according to a study...

The...

08/02/2016

Journal of Clinical Pathways

Research in Review

Vemurafenib Improves Response in Patients With Thyroid Cancer

07/28/2016

JCP Editors

Vemurafenib, a drug originally approved for use in patients with BRAF-positive melanoma, has also shown promising anti-tumor activity in some patients harboring this same mutation in thyroid cancer, according to the...

...

07/28/2016

Journal of Clinical Pathways

Research in Review

Ipilimumab Combination Significantly Improves Melanoma Outcomes

07/27/2016

JCP Editors

Ipilimumab (Yervoy; Bristol-Myers Squibb) combined with local peripheral treatments such as radiotherapy or electrochemotherapy may significantly prolong survival in patients with melanoma compared with...

...

07/27/2016

Journal of Clinical Pathways

Research in Review

Genetic Variant of Rectal Cancer Predicts Prognosis, Treatment Response

07/25/2016

JCP Editors

DNA mismatch repair (dMMR) deficiency rectal cancer is associated with excellent prognosis and pathologic response with current therapeutic options and surgical procedures, according to research published in the...

DNA...

07/25/2016

Journal of Clinical Pathways